Quick Answer
Quince Therapeutics, Inc. reported Diluted EPS of $1.31 per share (loss) for fiscal year 2024.
Quince Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.31 | -56.0% |
| 2023 | -$0.84 | +45.5% |
| 2022 | -$1.54 | +49.2% |
| 2021 | -$3.03 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.25 | -92.3% | +26.5% |
| June 30, 2025 | -$0.34 | +46.9% | +0.0% |
| March 31, 2025 | -$0.34 | -30.8% | -161.5% |
| September 30, 2024 | -$0.13 | +13.3% | +79.7% |
| June 30, 2024 | -$0.64 | -357.1% | -146.2% |
| March 31, 2024 | -$0.26 | +23.5% | -73.3% |
| September 30, 2023 | -$0.15 | +31.8% | -7.1% |
| June 30, 2023 | -$0.14 | +72.5% | +58.8% |
- Quince Therapeutics, Inc. showed a decrease of -56.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, Quince Therapeutics, Inc.’s diluted eps has grown by 56.8% (from $3.03 per share (loss) to $1.31 per share (loss)).
- The most recent figure is from Quince Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: